April 15, 2011
Safety Of Stored Blood Among Chief Concerns For Transfusion Medicine Community
Medical literature addresses possible adverse effects with older red cells; delivery of oxygen
In light of recent studies that suggest the use of stored blood during transfusions may cause adverse effects in patients, the National Heart, Lung, and Blood Institute (NHLBI) funded a number of research projects to examine the safety of transfusing older red cells and the impact of stored blood on respiratory gases. These papers discussing potential adverse effects of stored blood and related concerns for oxygen delivery by transfusion are now available online in TRANSFUSION, a journal published by Wiley-Blackwell on behalf of AABB.
"The most critical issue facing transfusion medicine is whether or not stored (older) blood is less safe than fresher blood," explains Paul M. Ness, M.D., Director of Transfusion Medicine at Johns Hopkins Medical Institute in Baltimore, MD, and Editor-in-Chief of TRANSFUSION. "Although emerging infectious disease risks and transfusion reactions are important concerns, there is nothing more imperative to our patients than making sure the methods we use to collect and store red cells do not impair their transport of vital respiratory gases."
Current Food and Drug Administration (FDA) standards state that red cells may be stored under refrigeration for a maximum of 42 days, or frozen for up to ten years. NBCUS 2007 data reported the mean age of stored red cells at the time of transfusion was 16 days. Medical evidence, however, has not been able to conclusively determine if stored blood adversely affects patients' health. In one prior study, trauma patients who received red cells stored beyond two weeks had a significantly increased risk of mortality compared to those transfused with fresher blood (Weinberg et al., 2010). Conversely, a study by Edgren et al., analyzed close to 405,000 transfusions between 1995 and 2002 and found no significant association between age of blood and seven-day mortality.
Controlled clinical trials in cardiac surgery and intensive care units are under way, and are expected to provide the transfusion community with critical data regarding the adverse effects of stored blood use. "Findings from these trials will not be reported for several years," said Dr. Ness. "Our early publication of the NHLBI grant program studies provides the transfusion community with a head start in learning more about what makes stored blood old, and provides advance opportunity for commercial industry to develop improved methods of blood storage that will mitigate adverse effects in patients."
On the Net: